| 11.25 0.25 (2.27%) | 06-18 14:44 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.62 | 1-year : | 22.19 |
| Resists | First : | 15.94 | Second : | 19 |
| Pivot price | 15.38  |
|||
| Supports | First : | 11 | Second : | 9.15 |
| MAs | MA(5) : | 12.84 |
MA(20) : | 16.03 |
| MA(100) : | 17.52 |
MA(250) : | 16.06  |
|
| MACD | MACD : | -1.3 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 19.1 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 22.14 | Low : | 5.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ZIVO ] has closed above bottom band by 7.7%. Bollinger Bands are 106.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.26 - 11.32 | 11.32 - 11.36 |
| Low: | 11.12 - 11.18 | 11.18 - 11.24 |
| Close: | 11.15 - 11.25 | 11.25 - 11.34 |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Fri, 20 Jun 2025
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry | ZIVO Stock News - GuruFocus
Fri, 20 Jun 2025
Major Breakthrough: ZIVO's Non-Antibiotic Immune Technology Gets Backing From Global Animal Health Giant - Stock Titan
Wed, 11 Jun 2025
Zivo Bioscience Announces Board Election and Approvals - TipRanks
Fri, 23 Aug 2024
Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO) - Yahoo Finance
Thu, 15 Aug 2024
Marquis Who's Who Honors Nola E. Masterson for Expertise in Investing - 24-7 Press Release Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.37e+006 (%) |
| Held by Institutions | 1.77e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.33 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 871.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -2.12 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 35470 |
| Forward Dividend | 12810 |
| Dividend Yield | 315289% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|